Jardiance Mortality Claim Narrowly Endorsed By FDA Advisory Committee
This article was originally published in The Pink Sheet Daily
Executive Summary
The 12-11 vote supporting new indication for reduced incidence of cardiovascular death provides cover for FDA if it decides more data are needed before granting first CV benefit claim to a diabetes drug.
You may also be interested in...
Boehringer's Empagliflozin Heads To Advisory Cmte. With Questions On Treatment Effect
Boehringer wants supplemental empagliflozin claim as insulin adjunct to improve glycemic control in type 1 diabetes, but US FDA questions the size of the clinical benefit and the magnitude of a diabetic ketoacidosis risk.
US FDA May Change Requirements For CV Outcomes Trials For Type 2 Diabetes Drugs
Endocrinologic and Metabolic Drugs Advisory Committee will reconsider 2008 guidance on evaluating CV risks in antidiabetic therapies at two-day meeting in October.
Victoza’s Non-Cardio Safety May Dominate At FDA Panel Review
US FDA does not raise any major concerns about study’s design or results to support cardiovascular risk reduction claim for Novo Nordisk’s GLP-1 agonist liraglutide ahead of advisory committee, but agency gives close scrutiny to non-CV safety events of interest.